Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v3-EN
Language French English
Date Updated 2019-07-19 2019-07-19
Drug Identification Number 02369524 02369524
Brand name JEVTANA JEVTANA
Common or Proper name Jevtana Jevtana
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients CABAZITAXEL CABAZITAXEL
Strength(s) 40MG 40MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 1 1
ATC code L01CD L01CD
ATC description PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2019-07-27 2019-07-27
Actual start date
Estimated end date 2019-08-30 2019-08-30
Actual end date 2019-07-18 2019-07-18
Shortage status Avoided shortage Avoided shortage
Company comments Temporary supply delay. Allocation has been initiated based on historical sales. It is recommended that no new treatment be initiated, to reserve the supplies to patients already under treatment. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Temporary supply delay. Allocation has been initiated based on historical sales. It is recommended that no new treatment be initiated, to reserve the supplies to patients already under treatment. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments